Editing Abbott Laboratories (section)

=== 21st century ===
In 2001, the company acquired Knoll, the pharmaceutical division of [[BASF]], for $6.9&nbsp;billion.<ref>{{Cite news |url=https://www.chicagotribune.com/2001/03/03/abbott-closes-early-on-knoll-acquisition/ |title=Abbott Closes Early On Knoll Acquisition |date=March 3, 2001 |work=Chicago Tribune}}</ref> In 2002, it divested the [[Selsun Blue]] brand to [[Chattem]].<ref>{{Cite news |url=https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |title=Company News; Chattem Buys Selsun Blue Shampoo Brand From Abbott |date=March 6, 2002 |work=The New York Times |agency=Reuters |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |url-status=live }}</ref> Later in 2002, it sold [[Clear Eyes]] and Murine brands to [[Prestige Brands]].<ref>{{Cite web |last=Smith |first=Scott S. |date=January 11, 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref> In 2004,  it acquired TheraSense, a [[diabetes]]-care company, which it merged with its MediSense division to become Abbott Diabetes Care.<ref>{{Cite news |last=Sandred |first=Jan |date=January 14, 2004 |title=$1 billion medical deal / Abbott Labs to buy Therasense, maker of glucose monitors |url=https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |work=SFGATE |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |url-status=live }}</ref>{{additional citation needed|date=June 2020}} In 2006, Abbott assisted [[Boston Scientific]] in its purchase of [[Guidant]] Corporation purchasing the vascular device division of Guidant.<ref>{{Cite news |last1=Feder |first1=Barnaby |last2=Sorkin |first2=Andrew Ross |date=January 18, 2006 |title=Boston Scientific, With Abbott's Help, Raises Bid for Guidant |url=https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |url-status=live }}</ref><ref>{{Cite news |last=Feder |first=Barnaby |date=September 27, 2006 |title=Johnson & Johnson Sues Boston Scientific, Guidant and Abbott Laboratories Over Deal |url=https://www.nytimes.com/2006/09/27/business/27device.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2006/09/27/business/27device.html |url-status=live }}</ref>

In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.<ref>{{cite news |last=Smith |first=Scott S. |date=11 January 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref> At the time of acquisition Kos marketed Niaspan (extended release [[niacin (substance)|niacin]]), and Advicor ([[niacin/lovastatin]]).

In 2007 the company was to sell two diagnostics divisions to [[General Electric]], but the parties did not agree on the terms of the acquisition.<ref>{{cite news | last1=Layne | first1=Rachel | last2=Lopatto | first2=Elizabeth | url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | title=GE, Abbott End $8.13 Billion Diagnostic Sale Deal (Update2) | agency=Bloomberg News | date=11 July 2007 | access-date=5 March 2017 | archive-date=24 September 2015 | archive-url=https://web.archive.org/web/20150924153211/http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | url-status=live }}</ref>

On 8 September 2007, the company sold the UK manufacturing plant at [[Queenborough]] to UK manufacturer Aesica Pharmaceuticals.<ref>{{Cite web |url=https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |title=Aesica Containment Facility |date=November 7, 2013 |website=Pharmaceutical Technology |access-date=10 March 2024 |archive-date=7 June 2023 |archive-url=https://web.archive.org/web/20230607023207/https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |url-status=live }}</ref><ref>{{Cite news |last=Tighe |first=Chris |date=July 8, 2007 |title=Aesica seizes some bargain buys |url=https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |work=Financial Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |url-status=live }}</ref>

Abbott's Ross Products was renamed Abbott Nutrition in 2007.<ref>{{Cite web |last=Wilson |first=Paul |title=End of an era: Abbott retires Ross Products name |url=https://www.dispatch.com/story/news/2007/11/08/end-era-abbott-retires-ross/24057637007/ |access-date=2020-04-02 |website=The Columbus Dispatch |language=en}}</ref>

In 2009 Abbott acquired [[Advanced Medical Optics]] of [[Santa Ana, California]], selling it to [[Johnson & Johnson]] in 2017.<ref>{{cite web|url=https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|title=Johnson & Johnson completes $4.3B acquisition of Abbott Medical Optics in Santa Ana|website=Orange County Register|date=28 February 2017|access-date=22 November 2019|archive-date=2 December 2022|archive-url=https://web.archive.org/web/20221202033619/https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|url-status=live}}</ref> In 2009, Abbott opened a satellite research and development facility at [[Research Park, University of Illinois at Urbana-Champaign]].<ref>{{cite web|url=https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|title=Abbott Labs leasing space in UI research park|website=The News Gazette|date=2 May 2009|access-date=22 November 2019|archive-date=20 November 2022|archive-url=https://web.archive.org/web/20221120024440/https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|url-status=live}}</ref>

In February 2010, Abbott acquired the pharmaceuticals unit of [[Solvay S.A.]] for [[US$]]6.2 billion ([[€]]4.5 billion),<ref>{{cite web|url=http://www.abbott.com/news-media/press-releases/Press_Release_0819.htm |title=Abbott Completes Acquisition of Solvay Pharmaceuticals |author=Abbott Press Release |date=16 February 2010 |access-date=22 March 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120312235321/http://www.abbott.com/news-media/press-releases/Press_Release_0819.htm |archive-date=12 March 2012 }}</ref> gaining many additional pharmaceutical products and an increased presence in emerging markets.<ref name="Abbott-Feb-2010-8-K">{{cite web |url=http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |title=Abbott Laboratories Feb 2010 Current Report, Form 8-K, Filing Date Feb 16, 2010 |publisher=secdatabase.com |access-date=27 December 2012 |archive-date=23 May 2013 |archive-url=https://web.archive.org/web/20130523222642/http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |url-status=live }}</ref>

In 2010 the company acquired [[Hollywood, Florida]]-based [[laboratory information management system]] company [[STARLIMS]] for $123 million, $14 per share.<ref>{{Cite news |url=https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |title=Abbott sets deal to buy Starlims |date=December 15, 2009 |work=Chicago Tribune |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |url-status=live }}</ref><ref>{{Cite press release |url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-starlims-technologies-88846137.html |title=Abbott Completes Acquisition of STARLIMS Technologies |date=March 22, 2010 |publisher=PR Newswire}}</ref> That year Abbott said it would buy [[Piramal Group|Piramal Healthcare]] of India's large generic drugs unit for $3.72 billion.<ref>{{cite news|url=https://www.wsj.com/articles/SB10001424052748704852004575257614197847830|title=Abbott Labs to Buy Indian Business|author=Peter Loftus and Rumman Ahmed|work=The Wall Street Journal|access-date=26 September 2019|archive-date=5 August 2023|archive-url=https://web.archive.org/web/20230805093503/http://www.wsj.com/articles/SB10001424052748704852004575257614197847830|url-status=live}}</ref><ref>Abbott 2011 annual report, p43</ref>